Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: 5-amino-1-methylquinolinium · 5-amino-1mg (source spelling; identity to confirm)
Nonpeptide agent · Nonpeptide small molecule
Detailed molecular class: Non-peptide small molecule
Supplied sequence or chemical reference
PubChem CID: 950107
Molecular formula: C10H11N2+
IUPAC: 1-methylquinolin-1-ium-5-amine
Source: PC-5-AMINO-1MQ
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
NNMT inhibition; NNMT methylates nicotinamide, not NAD directly.
Evidence and critical reading
Reported scientific and empirical uses
Reported weight management
Small-molecule NNMT inhibitor sold alongside peptides; not a peptide.
Human evidence
No clinical obesity or longevity efficacy established by the cited mouse study.
Preclinical evidence
Diet-induced obesity experiments in mice.
Critical reading and limitations
The selected obese-mouse study establishes neither human efficacy nor equivalence of commercial salts.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Human toxicity, interactions and therapeutic window unresolved.
No validated human regimen; systemic enzyme inhibition/interactions cannot be declared harmless.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
5-amino-1MQ · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-5-AMINO-1MQ
PubChem 5-amino-1-methylquinolinium (CID 950107)
October 16, 2026
- PMID29155147
Neelakantan H, Vance V, Wetzel MD, Wang HL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ.
October 16, 2026
- R26
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026